Wednesday, July 8, 2026

Patent intelligence · US

US 8403910

Drug releasing coatings for medical devices

granted A61KA61K31/337A61K31/436A61K45/06
Status granted
Linked drugs 2
Pipeline programs 6
Years to expiry 7
Applicant portfolio 86
Patent details — US 8403910
Jurisdiction
US
Status
granted
Grant date
Mar 26, 2013
Expiration
Mar 21, 2033
Applicant
Lutonix, Inc.
Claims
36
CPC classes
A61K, A61K31/337, A61K31/436, A61K45/06
View on Google Patents ↗

Quick answer

US 8403910 (Drug releasing coatings for medical devices) is held by Lutonix, Inc.. Status: granted. Granted Mar 26, 2013. Expires Mar 21, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Applicant
Lutonix, Inc.
Grant date
Expiration
Claims
36
CPC classes
A61K, A61K31/337, A61K31/436, A61K45/06, A61P, A61P11/00

More from Lutonix, Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 12383733

    Iontophoresis-based patch type medicine absorption device

    ROOTONIX Co., Ltd. · Expires Aug 7, 2045

    granted
  2. US 12365879

    Synthetic chimeric poxviruses

    TONIX PHARMA LIMITED · Expires Jul 17, 2045

    granted
  3. US 12304901

    Selective ligands for tau aggregates

    Sentonix, Inc. · Expires May 15, 2045

    granted
  4. US 12156897

    Magnesium-containing oxytocin formulations and methods of use

    TONIX PHARMA LIMITED · Expires Nov 28, 2044

    granted
  5. US 12156864

    Analogs of cyclobenzaprine and amitryptilene

    TONIX PHARMACEUTICALS HOLDING CORP · Expires Nov 28, 2044

    granted
  6. US 12097183

    Pharmaceutical composition for treating migraine

    Tonix Medicines, Inc. · Expires Sep 19, 2044

    granted
  7. US 12090139

    Formulations comprising triptan compounds

    Tonix Medicines, Inc. · Expires Sep 12, 2044

    granted
  8. US 11998516

    Methods and compositions for treating depression using cyclobenzaprine

    TONIX PHARMA LIMITED · Expires May 30, 2044

    granted

Frequently asked questions

What is US patent 8403910?

US 8403910 (Drug releasing coatings for medical devices) is held by Lutonix, Inc.. Status: granted. Granted Mar 26, 2013. Expires Mar 21, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 8403910?

Lutonix, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 86 pharmaceutical patents for this assignee.

When does US 8403910 expire?

Our index shows an expiration date of Mar 21, 2033 (7 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.